Abstract
The role of μ-opioid receptor (MOR) down-regulation in opioid tolerance remains controversial. In this study, we used a novel knock-in mouse to examine how changing the extent of MOR down-regulation alters the development of morphine tolerance. These mice express a mutant MOR, degrading MOR (DMOR), that differs from the wild-type (WT) MOR in two ways: 1) unlike the recycling WT MOR, the mutant DMOR is targeted for degradation after its internalization, thus facilitating down-regulation; and 2) unlike the WT MOR, DMOR is efficiently internalized in response to morphine activation. We found that both WT MOR and DMOR mice develop tolerance to morphine, but DMOR mice exhibit a more rapid onset of tolerance and show receptor down-regulation. WT MOR mice develop morphine tolerance more slowly but even once profoundly tolerant show no receptor down-regulation. Furthermore, WT mice show significantly more morphine dependence than DMOR mice after long-term treatment as indicated by withdrawal. Taken together these data indicate that tolerance mediated by receptor down-regulation manifests differently both at the behavioral and biochemical level than does the actual morphine tolerance that occurs in WT mice and that loss of receptor function is not a major contributor to morphine tolerance in WT MOR mice.
Footnotes
This work was supported by the National Institutes of Health National Institute on Drug Abuse [Grants DA015232, DA019958]; State of California funds for medical research on alcohol and substance abuse through the University of California San Francisco (to J.J.W.); and the European Molecular Biology Organization [Fellowship ALTF1229-2006] (to J.E.).
Article, publication date, and citation information can be found at http://jpet.aspetjournals.org.
doi:10.1124/jpet.111.179754.
↵ The online version of this article (available at http://jpet.aspetjournals.org) contains supplemental material.
-
ABBREVIATIONS:
- MOR
- μ-opioid receptor
- CNS
- central nervous system
- DMOR
- degrading μ-opioid receptor
- WT
- wild type
- GTPγS
- guanosine 5′-(γ-thio)triphosphate
- DAMGO
- [d-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin
- Tricine
- N-[2-hydroxy-1,1-bis(hydroxymethyl)ethyl]glycine
- kb
- kilobase
- PBS
- phosphate-buffered saline
- MPE
- maximal possible effect
- ANOVA
- analysis of variance
- HEK
- human embryonic kidney
- MS
- morphine sulfate.
- Received January 24, 2011.
- Accepted May 4, 2011.
- Copyright © 2011 by The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|